Medtronic PLC $MDT Position Increased by Quadrant Capital Group LLC

Quadrant Capital Group LLC boosted its position in shares of Medtronic PLC (NYSE:MDT) by 113.2% in the third quarter, Holdings Channel.com reports. The firm owned 32,376 shares of the medical technology company’s stock after purchasing an additional 17,191 shares during the period. Quadrant Capital Group LLC’s holdings in Medtronic were worth $3,083,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Corundum Trust Company INC acquired a new position in Medtronic in the 3rd quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter valued at about $29,000. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic in the 2nd quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medtronic in the 3rd quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in Medtronic in the third quarter worth approximately $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is owned by company insiders.

Medtronic Trading Down 1.0%

Shares of MDT stock opened at $88.97 on Thursday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The business’s 50 day moving average is $98.31 and its two-hundred day moving average is $96.94. The company has a market cap of $114.23 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 2.26 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.2%. Medtronic’s payout ratio is currently 79.11%.

Analyst Upgrades and Downgrades

MDT has been the topic of several recent research reports. Mizuho raised shares of Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Sanford C. Bernstein increased their price target on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Daiwa Securities Group cut their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $110.74.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced a definitive agreement to acquire Scientia Vascular for $550 million to strengthen its neurovascular access and therapeutic portfolio — a strategic buy that expands Medtronic’s stroke/aneurysm workflow coverage and supports longer-term growth in neurovascular procedures. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Positive Sentiment: New data highlight clinical benefit for the Symplicity Spyral renal denervation system — evidence that can support commercial adoption and reimbursement discussions for hypertension interventions. Medtronic data highlights clinical benefit of Symplicity Spyral renal denervation
• Positive Sentiment: Medtronic elevated long-time executive Sean Haag to president of its ENT business and to the neuroscience leadership team — an internal leadership move intended to accelerate ENT strategy execution and cross-group coordination. Medtronic elevates Sean Haag to president of ENT
• Neutral Sentiment: Management presentations/transcripts from investor conferences (Leerink and Barclays) provide updated commentary on strategy, margins and product cadence but didn’t introduce a clear new catalyst — useful for modelling but not market-moving on their own. Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and valuation checks are flagging recent share-price weakness and asking whether MDT is attractively priced after declines — this frames investor debate between buying the dip vs. waiting for clearer growth signals. Is Medtronic (MDT) Pricing Look Attractive After Recent Share Price Weakness
• Neutral Sentiment: Analyst coverage roundup offers a range of opinions and price targets — helpful for tracking consensus but not a single directional catalyst. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Negative Sentiment: Competitor Intuitive Surgical’s strong momentum with da Vinci 5 and expanding procedure volumes underscores robotic platform adoption that could pressure legacy procedure mix and market share dynamics in some surgical categories. Intuitive Surgical Poised for Growth in 2026 on da Vinci 5 Momentum
• Negative Sentiment: NeuroPace’s product and reimbursement progress (RNS adoption, AI seizure detection) highlight competitive advances in neuromodulation that may influence neurology market dynamics where Medtronic also competes. NeuroPace’s Seizure ID and New Indication Could Expand RNS Demand

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).